Ann: Incannex to Acquire APIRx Pharmaceuticals, page-73

Brilliant acquisition:

• 19 Granted patents
• 23 Pending patents
• 4 Pre Ind meetings
• 4 Phase 2 trials
• 26 million Euro (approx 40m AUD) spent on development

We are putting together a significant company that could well be the next GW Pharma. Love all the 5 minute analysis out there but the due diligence on this would have been done over many months and I am backing the in depth analysis the BOD would have done.

Ex entitlement we have held up extremely well and I would not be surprised to see us green this afternoon with moves North as the next couple weeks go by. Either way we have just added to our IP. The very thing that makes you a buy out possibility and the very thing that de-risks your company if a trial here or there doesn't go to plan. My view, trust in the BOD Commercial decision, the runs are on the board there!